(firstQuint)Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer.

 Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms: - Topotecan - Docetaxel For ever 2 patients treated, 1 will receive treatment A (Topotecan) and 1 will receive treatment B (Docetaxel).

 The study is not blinded so both the patient and the doctor will know which treatment has been assigned.

.

 Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer@highlight

In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.

